ATHERONOVA INC. AtheroNova Inc. announced that Randolph M. Johnson, Ph.D. has joined the company as Chief Operating Officer. Dr. Johnson has established a successful track record in pharmaceutical research and development and operations with 25 years of experience in the biotech, pharmaceutical, drug delivery and medical device businesses in both start-ups and preeminent global companies. He has experience in successful entrepreneurial financing, corporate funding alliances/joint ventures and IPO launches.
His in-depth scientific experience is heavily concentrated in the areas of cardiovascular disease, oncology, endocrinology, and neurology. Prior to AMGEN/KAI, Dr. Johnson served as Senior Vice President of Research and Preclinical Development for Cellgate, providing leadership in the R&D of novel molecular transporters and polyamine analogs for hyperproliferative diseases before the company was acquired by Progen, a public Australian pharmaceutical company.
